Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of MK-2010 monotherapy in malignant neoplasms
jRCT2030260578Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of LM-299 in cancer, sponsored by Merck & Co. Primary endpoints: Number of participants with adverse events, Number of participants who discontinue study treatment due to an adverse event and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
LM-299
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2030260578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2030260578.